Androgen receptor directed therapy of breast cancer – pro
The androgen receptor (AR) is a proven clinical target in prostate cancer. Recent research indicates that it is an emerging hormonal target in breast cancer as well, with potential clinical benefit in both estrogen receptor(ER) positive and negative tumors. Compared to the ER, AR contains unique functional domains with relevance to its altered role in human breast cancer. The majority of ER-positive tumors express AR, and a significant percentage of ER-negative tumors might benefit from combined targeting of AR and the ErbB2/HER2 oncogene. Signaling downstream of AR might also affect many clinically important pathways which are also emerging clinical targets in breast cancer. AR expression might also play a role during tumor progression to metastatic disease, and is promising in triple negative breast cancer. However routine use of Xtandi remain E/I at this time.
Majumder A, Singh M, Tyagi SC. Oncotarget. 2017 Nov 24; 8(60):102739-102758. Epub 2017 Oct 27.
Iacopetta D, Rechoum Y, Fuqua SA. The Role of Androgen Receptor in Breast Cancer. Drug Discov Today Dis Mech. 2012;9(1-2):e19–e27. doi:10.1016/j.ddmec.2012.11.003